

**TEST INFORMATION UPDATE**  
**IBD CLINICAL DRUG MONITORING**

**Effective Date: April 12th, 2023**

Effective April 12<sup>th</sup>, 2023, HaliuDx biologic assay testing was discontinued.

VUMC will no longer send these samples to Veracyte Diagnostics for testing. New Mayo Clinic Laboratories referral tests are now available in eSTAR.

<b><u>DISCONTINUED TEST</u></b>	<b><u>NEW TEST</u></b>
Adalimumab (Humira)-HLDX [LAB6184]	Adalimumab Qt w/Rfx to Ab-MAYO [LAB6548]
Certolizumab (Cimzia)-HLDX [LAB6185]	Certolizumab and Anti-Certo Ab-MAYO [LAB6543]
Golimumab (Simponi)-HLDX [LAB6186]	Golimumab w/Ab-MAYO [LAB6544]
Infliximab-dyyb (Inflectra)-HLDX [LAB6189], Infliximab-abda (Renflexis)-HLDX [LAB6188], Infliximab (Remicade)-HLDX [LAB6187]	Infliximab Qt w/Rfx to Ab-MAYO [LAB6550]
Ustekinumab (Stelara)-HLDX [LAB6190]	Ustekinumab Qt w/Ab-MAYO [LAB6545]
Vedolizumab (Entyvio)-HLDX [LAB6191]	Vedolizumab Ab-MAYO [LAB6546]

**PLEASE NOTE:** Patients being monitored for treatment response by these tests should be **re-baselined**.

Detailed test information, including specimen collection requirements, is available online at [www.labVU.com](http://www.labVU.com).

For more information or assistance, please get in touch with Lab Customer Service at 615-875-5227 (5-LABS)